22nd Century Granted FDA Guidance Meeting for X-22 Smoking Cessation Aid
March 2, 2017 at 6:59 am
CLARENCE, N.Y.--(BUSINESS WIRE)-- 22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on reducing the harm caused by smoking, announced today that the Company has been granted a guidance meeting with the Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA) to discuss “X-22,” which the Company is developing as its signature smoking cessation aid. At the meeting, which will take place this June, the Company will seek agreement from CDER/FDA on an appropriate path for X-22 to become a prescription-based cessation aid for smokers in the United States.
